- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Approves Boston Scientific’s Deep Brain Stimulation Software
Company aims to utilize technology for efficient Parkinson’s treatment.
Boston Scientific Corporation has announced the FDA approval of its Vercise™ Neural Navigator 5 Software. According to the company, when this software is used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) systems, it will offer clinicians the data for programming in the treatment of people living with Parkinson’s disease or essential tremor.
"Developing meaningful tools to help physicians provide personalized treatments for their patients delivers on our promise to advance our technologies for people living with neurological conditions,” said Jim Cassidy, president, neuromodulation, Boston Scientific, in a company press release. “Providing effective DBS therapy is complex and can be time-consuming. This software will help streamline the process and allow for more doctor-patient interaction time."
Reference: Boston Scientific Receives FDA Approval for the Next Innovation in Image Guided Programming Software for Deep Brain Stimulation. Boston Scientific. July 11, 2023. Accessed July 18, 2023. https://news.bostonscientific.com/Boston-Scientific-Receives-FDA-ApprovNext-Innovation-Image-Guided-Programming-Software-Deep-Brain-Stimulation
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
